IQ-AI Limited

IQAI

JE00BD4H0R42

Healthcare Facilities & Services

Market Closed - London S.E. Other stock markets 11:35:24 2024-07-11 am EDT			5-day change	1st Jan Change
1.1 ^GBX	0.00%		0.00%	-76.60%

Jun. 25	IQ-AI subsidiary opens expanded access programme	AN
Jun. 14	IQ-AI Says Brain Cancer Drug Delays Disease Progression in Early-stage Study	MT

IQ-AI Limited Appoints Michael Schmainda as Non-Executive Director

December 18, 2019 at 07:46 am EST

IQ-AI Ltd. announced the immediate appointment of Michael Schmainda as Non-Executive Director.

Latest news about IQ-AI Limited

IQ-AI subsidiary opens expanded access programme	Jun. 25	AN
IQ-AI Says Brain Cancer Drug Delays Disease Progression in Early-stage Study	Jun. 14	MT
IQ-AI team begins defining phase 2 protocol for oral gallium maltolate	Jun. 14	AN
IQ-AI Ltd. Provides Update on Phase 1 Update	Jun. 14	CI
Celadon ships to US; Oxford BioDynamics-Goodbody pact	May. 23	AN
IQ-AI subsidiary gets second FDA rare paediatric disease designation	May. 20	AN
IQ-AI's Imaging Biometrics Gets Second Rare Disease Designation for Drug Candidate	May. 20	MT
Ingenta trades in line; Triple Point Social NAV up	May. 17	AN
IQ-AI Unit Delivers Software to Insel Gruppe	May. 17	MT
IQ-AI subsidiary gets rare paediatric disease designation FDA	May. 10	AN
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	May. 10	MT
EARNINGS AND TRADING: Trident Royalties swings to profit	May. 02	AN
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	Apr. 29	CI
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
IQ-AI's Broker Exercises Option to Buy Shares in Placing	Feb. 26	MT
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	Feb. 22	MT
IQ-AI shares sink on discounted placing fundraise	Feb. 22	AN
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	Feb. 09	MT
IQ-AI subsidiary asked by FDA to resubmit and modify application	Feb. 09	AN
IQ-AI Unit Secures Grant for Brain Tumor Pill Access Program	Feb. 02	MT
IQ-AI celebrates USD100,000 grant for subsidiary	Feb. 02	AN
IQ-AI falls after subsidiary notes launch of treatment access scheme	Jan. 10	AN
IQ-AI's Imaging Biometrics Plans Expanded Access Program for Brain Tumor Treatment	Jan. 10	MT
IQ-AI Subsidiary’s Glioblastoma Therapy Obtains Fast-Track Designation From US FDA	Dec. 19	MT
IQ-AI firm gets US FDA fast-track status for oral gallium maltolate	Dec. 19	AN

IQ-AI Limited is a Jersey-based company, which is engaged in the provision of clinical treatments to patients in the field of medical imaging diagnostics, based on technology. The Company operates through two segments: holding company expenses and medical software. Its subsidiaries include Imaging Biometrics, LLC and Stone Checker Software Limited. Imaging Biometrics, LLC is a healthcare imaging software company. In addition to providing regulatory consulting services, Imaging Biometrics, LLC supplies medical technology solutions and has a neuroimaging product portfolio. Stone Checker Software Limited is a supplier of technology solutions in the field of kidney stone analysis and kidney stone prevention.

Sector

Healthcare Facilities & Services

Calendar

2024-09-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
IQ-AI LIMITED	-76.60%	3.13M
SONIC HEALTHCARE LIMITED	-17.66%	8.37B
RADNET, INC.	+72.10%	4.15B
DR. LAL PATHLABS LIMITED	+14.30%	2.94B
SYNLAB AG	-2.98%	2.64B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-54.55%	1.76B
NEOGENOMICS, INC.	-11.31%	1.73B
FLEURY S.A.	-13.41%	1.56B
METROPOLIS HEALTHCARE LIMITED	+22.65%	1.26B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-46.45%	1.07B